Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
5 golden rules of investing to help you thump the market
⏸️ Investing
Credit Suisse: Brambles Limited shares are a buy
⏸️ Investing
What to watch on the ASX this week
⏸️ Investing
Why the Nuheara Ltd share price rocketed 26% higher today
⏸️ Investing
Could the Cochlear Ltd share price crack $200 in 2018?
⏸️ Investing
The Cochlear Limited share price just hit a record high
⏸️ Investing
Broker's simple tip on picking healthcare winners in 2018
⏸️ Investing
4 companies I like that are well placed to withstand rising interest rates
⏸️ Investing
Will the Reserve Bank's meeting impact the ASX this week?
⏸️ Investing
3 fast growing dividend shares
⏸️ Investing
The easiest way to crush the ASX in 2018
⏸️ Investing
2 investing themes I'm betting on to grow my wealth
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
